![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1269703
¼¼°èÀÇ ¾È°ú Áúȯ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : ¾à¹° À¯Çüº°, ¿ë·®º°, ÀûÀÀÁõº°, ÀûÀÀÁõ Áúȯº°, À¯Åë ä³Îº°, Áö¿ªº° ºÐ¼®(2022-2029³â)Global Ophthalmic Disease Therapeutics Market Size Study & Forecast, by Drug Class by Dosage Form, by Disease Indication, by Distribution Channel and Regional Analysis, 2022-2029 |
¼¼°è ¾È°ú Áúȯ Ä¡·áÁ¦ ½ÃÀåÀº 2021³â ¾à 315¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç, 2022-2029³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 6.4% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
³ì³»Àå, ¾È±¸°ÇÁ¶Áõ, ¸Á¸·Áúȯ µî ´Ù¾çÇÑ ¾È°ú ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ ¾à¹°°ú Ä¡·áÁ¦°¡ ¾È°ú Áúȯ Ä¡·áÁ¦ ½ÃÀå¿¡ Æ÷ÇԵ˴ϴÙ. ¾È°ú Áúȯ Ä¡·áÁ¦ ½ÃÀåÀº ¾È°ú ÁúȯÀÇ À¯º´·ü Áõ°¡, Çõ½ÅÀûÀÎ ÀǾàǰ ¹× Ä¡·áÁ¦ÀÇ ÀÓ»ó½ÃÇè ¹× ÆÄÀÌÇÁ¶óÀÎ Èĺ¸¹°Áú Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.
¼¼°èÀûÀ¸·Î ³ì³»Àå, ¸Á¸·Áúȯ, ¾È±¸°ÇÁ¶Áõ°ú °°Àº ¾È°ú ÁúȯÀÇ À¯º´·üÀÌ »ó½ÂÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ¾È°úÇÐȸ(AAO)ÀÇ 2020³â¿¡ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é, ¹Ì±¹¿¡¼´Â 300¸¸ ¸í(ÀÌÁß 40¼¼ ÀÌ»ó 270¸¸ ¸í)ÀÌ ³ì³»ÀåÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°èÀºÇà±×·ì¿¡ µû¸£¸é 2020³â ¼¼°è ³ëÀÎ Àα¸´Â 7¾ï 2,700¸¸ ¸íÀ¸·Î ÇâÈÄ 30³â°£ 3¹è Áõ°¡ÇØ 2050³â¿¡´Â 15¾ï ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´Ù¾çÇÑ ÀÇ·á ±â°ü, Á¤ºÎ ±â°ü ¹× ¾÷°è °ü°èÀÚµéÀÇ ³ë·Â, ±¹¹ÎµéÀÇ ¾ÈÁúȯ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÀÇ·áºñ Áõ°¡, ¼±Áø±¹°ú °³¹ßµµ»ó±¹ ¸ðµÎ¿¡¼ ¾È°ú ÀÇ»ç ¼ö Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¾ÈÁúȯ Ä¡·á¿¡ ´ëÇÑ ½ÃÀå ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿þÀÏÁî Á¤ºÎÀÇ 2021³â º¸°í¼¿¡ µû¸£¸é, ¿þÀÏÁîÀÇ ¾È°ú ÀÇ»ç ¼ö´Â 2020³â 3¿ù 885¸í¿¡¼ 2021³â 3¿ù 961¸íÀ¸·Î Áõ°¡Çß½À´Ï´Ù. ±×·¯³ª ¾È°ú Áúȯ Ä¡·áÁ¦ÀÇ ³ôÀº ºñ¿ëÀº 2022-2029³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.
Ophthalmic Disease Therapeutics ¼¼°è ½ÃÀå Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, Áß³²¹Ì ¹× ±âŸ Áö¿ªÀÔ´Ï´Ù. ºÏ¹Ì´Â Áø´Ü ¹× Ä¡·á ºñÀ² Áõ°¡¿Í ¸¹Àº ¾È°ú ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ¼öÀÍ Ãø¸é¿¡¼ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾È°ú ¹× ´« °Ç°À» À§ÇÑ ÀÇ·á ÁöÃâÀÌ Áõ°¡ÇÏ°í ´Ù¾çÇÑ ¾È°ú Áúȯ¿¡ ´ëÇÑ º¸ÀåÀÌ °ÈµÊ¿¡ µû¶ó ÀÌ Áö¿ªÀÇ ÁÖ¿ä ±¹°¡µéÀº ÷´Ü ¹× »õ·Î¿î Ä¡·á¹ýÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, À¯·´Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ³ë·É Àα¸ ¹× ´ë»ó Àα¸ Áõ°¡, Á¦Ç° °³¹ßÀ» À§ÇÑ °øµ¿ ¿¬±¸ Áõ°¡, ÁÖ¿ä ±â¾÷ÀÇ Áö¿ª È®Àå, Á¤ºÎ ¹× ºñ¿µ¸® ´ÜüÀÇ Àû±ØÀûÀÎ ½ÃÀå ÁøÀÔ µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.
ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â µ¿¾È ´Ù¾çÇÑ ºÎ¹® ¹× ±¹°¡º° ½ÃÀå ±Ô¸ð¸¦ Á¤ÀÇÇϰí ÇâÈÄ ¸î ³â µ¿¾È ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû, ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.
¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦ µî Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï ȯ°æ°ú °æÀï ±¸µµ¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚµéÀÌ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.
Global Ophthalmic Disease Therapeutics Market is valued at approximately USD 31.54 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.4% over the forecast period 2022-2029. Drugs and therapies for treating various ocular ailments such as glaucoma, dry eye disease, retinal diseases, and others are included in ophthalmic disease therapeutics. The Ophthalmic Disease Therapeutics market is expanding because of factors such as the rising prevalence of ophthalmic conditions and increasing clinical trials and pipeline candidates for Innovative Drugs and Therapies.
Globally, the prevalence of ophthalmic diseases such as glaucoma, retinal diseases, dry eye disease, and others is on the rise which is catering for market growth. According to a 2020 article from the American Academy of Ophthalmology (AAO), 3.0 million Americans, of whom 2.7 million are 40 years of age or older, have glaucoma. According to the World Bank Group, the world's old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050. The increasing number of initiatives taken by various healthcare organizations, governmental entities, and industry actors, there is a greater awareness among the public about ocular disorders, the market demand for treatments for ocular diseases is anticipated to be boosted by factors such as growing healthcare costs and an increase in the number of ophthalmologists in both developed and developing nations. According to the Welsh Government's 2021 report, The number of ophthalmic practitioners in Wales climbed to 961 in March 2021 from 885 in March 2020. However, the high cost of Ophthalmic Disease Therapeutics stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Ophthalmic Disease Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the increasing rates of diagnosis and treatment, as well as an increase in the prevalence of numerous ocular illnesses. Additionally, rising healthcare spending in the region supporting eye care and eye health, as well as acceptable compensation for a variety of ocular problems, encourage the region's major economies to adopt cutting-edge and novel treatments. Whereas Europe is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Classofferings of key players. The detailed segments and sub-segment of the market are explained below.